Your English writing platform
Discover LudwigExact(3)
Patients were more likely to take a mood stabilizer than any other drug.
In addition, patients had to take a mood stabilizer at the time of randomization or agree to begin treatment with a mood stabilizer.
To summarize, (1) patients were more likely to take a mood stabilizer than any other drug; (2) although most patients were taking polypharmacy, there were no predominant drug regimens even among those taking a stable combination; and (3) most patients with a stable combination take a relatively small number of drugs daily.
Similar(57)
And though I didn't drink any alcohol or take a mood-altering drug, I wrote in something of a drunken trance about the scarf, about my history with my mother, and how and where the two intersected.
At the time of assessment, 21% of patients were not taking any psychotropic medications; 33% were taking second-generation antidepressants, 49% were taking an atypical antipsychotic medication, 28% were taking a mood stabiliser (consisting of 8 subjects taking lithium and 20 taking anticonvulsants) and 3% were taking a stimulant.
I have never taken a mood stabilizer/anticonvulsant (such as lithium or Depakote), or had shock treatments or psychosurgery.
There he was treated for tuberculosis and began taking a mood stabilizing drug and an anti-psychotic, he said, both of which he still takes daily.
Of the 97 patients, 84 (86.6%) were taking a mood stabilizer.
One hundred eleven of these patients were also taking a mood stabilizer.
Since taking a mood stabilizer or antipsychotic for 100 days was required for analysis, the least adherent patients were excluded.
For the 111 individuals, there was no significant difference in the regularity for taking an antidepressant versus taking a mood stabilizer (p = 0.273).
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com